home > news > detailed info

Data custodianship of connected devices, environmental impact and adherence technologies highlighted at Pharmapack Europe 2020


Global biologics markets, delivery device innovation and smart packaging ‘unpacking’ new growth opportunities for pharma

Paris, 19th February 2020: Improving adherence to medication via smarter, patient-centric pharmaceutical packaging and extracting further value from existing medicines and delivery devices are two of the latest key strategies aimed at reducing waste and protecting the bottom line, according to experts at the recent Pharmapack Europe (#pharmapackeu). The event is widely seen as an excellent yardstick of the industry’s prospects for the year ahead. Encouragingly, the event played host a record 411 exhibiting companies, 5366 attendees and 325 delegates.

Europe’s leading pharmaceutical packaging and drug delivery event – which took place at the Paris Expo, Porte de Versailles, February 5-6 – featured many innovations as well as novel drug delivery solutions, with ‘waste management’, “connectivity” and “patient centricity” being some the key themes throughout this year’s edition.

A who’s who of pharma packaging and drug device innovators exhibited from Aptar, SHL, Stevanato Group and BD to Nemera and West Pharmaceutical Services – with several major new technologies and partnerships announced. But some of the most promising innovations were presented by emerging companies in the Start-up hub – with technologies featured from AI development platforms through miniaturized/non-intrusive sensors, to vial/ampule combination devices ad smart packaging.

The conference played host to four themed content sessions, while the learning labs and several educational and interactive workshops explored major industry changes that lie ahead. Aurelio Arias, Engagement Manager at IQVIA suggested during his session that ‘the future of Value-Added Medicines is not just driven by deeper Insights and data capture but will also see gamification transforming engagement of therapies’. Arias added that ‘while patients are concerned about the security and the custodianship of their data’, they are still actively using connected devices. As a result, the natural evolution of this trend could be that healthcare companies will increasingly incentivise better compliance through gamification.

Yet one area that connected devices perhaps lag begin other areas of pharma packaging and devices is in environmental impact. Gregor Anderson, Managing Director at Pharmacentric solutions believes that the industry still has a long way to go when it comes to the sustainability of connected devices, commenting on ‘the duality of connected devices’. On one hand, it is an exciting field of new possibilities, but unfortunately on the other, we have not yet ‘fully married them with our sustainability goals’. He believes that is the next evolution for the industry in the year ahead, as more devices and technologies are now moving into commercial applications

In the ‘Challenges in drug delivery for biologics’ session, experts agreed that combining biologic drug and device development, while meeting regulatory standards is a significant learning curve for the industry. Overall, drug delivery was seen as increasingly integral to the growth of the biologics market, with patient centricity an essential component in adherence. In the short term, this is projected to push manufacturers to provide better devices – that ease the patient experience. But in the long term, experts postulated connected devices will play a major role in the advancement of the biologics industry – with increasingly levels of vital data on how devices are used post launch.

In the ‘New horizons in innovation’ session, Marc Rohrschneider, Head New Technologies, Device Development and Commercialisation at Novartis AG predicted that with pharma now having access to technology to connect boxes, vials and devices to networks, the next decade is not about the technology challenges. But will instead explore how the industry safeguards data, and ultimately, who is its custodian. Blockchain is another industry buzzword of the last year, but experts at Pharmapack point to the improved accountability it could provide in pharma supply as its most immediate use, rather than in securing patient data. “You should think of it as the most secure audit trail you can have. Immutable, temporal and despite what many have said, scalable” commented Jason Lacombe, Chief Executive Officer, Veratrak. But the key to delivering on its potential is for pharma and tech communities to work closer together to deliver over the hype.

Silvia Forroova, Brand Director at Pharmapack Europe commented, “In the last few years, as our Pharmapack agenda is testament to, we have seen the rise of truly patient centric delivery forms, increasingly smart and child safe packaging, and a growing awareness of the vital role we can play in bringing about a more environmentally friendly industry. But what we are also seeing is that by bringing different groups together we are reinventing the art of the possible. It’s one of the greatest strengths of Pharmapack that we provide a platform to help build networks and communities, share learning and celebrate new innovations. Our experience of this event in 2020 is that the industry looks well set for growth in the year ahead and we can expect to see more collaborations in an age when the delivery of products is changing quickly. This is great news for drug delivery and packaging companies, but even better news for patients.”

Pharmapack Europe 2021 return to the Paris Expo, Porte De Versailles in Paris between the 27 & 28 January and is the leading hub for stakeholders across all parts of the pharmaceutical packaging and drug delivery supply chain.

To exhibit at next year’s show, please visit:
phone +31(0)20 708 1637
email Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France
Print this page
Send to a friend
News and Press Releases

Cargo Convoy Departs to China Carrying Medical Supplies Donated by Qatar Airways for Coronavirus Relief

2,500,000 face masks and 500,000 bottles of hand sanitizer have been donated by Qatar Airways
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement